Currently Viewing:
Currently Reading
Sanofi Reports LixiLan-L Topline Results; Says Combo Superior to Insulin Alone
September 14, 2015 – Mary K. Caffrey
Vitamin C May Help Overweight Patients Who Won't Exercise
September 08, 2015 – Mary K. Caffrey
DPP-4 Inhibitors Subject of FDA Safety Warning
September 07, 2015 – AJMC Staff
What Can Mouse Gut Bacteria Teach Us About Obesity?
September 04, 2015 – Mary K. Caffrey
Young at Heart? Most Americans Aren't, CDC Research Finds
September 03, 2015 – Mary K. Caffrey
"Happy Meal" Study Gives New Life to NYC Council Proposal
September 02, 2015 – Mary K. Caffrey
Dexcom G5 Mobile CGM System Approved by FDA
September 01, 2015 – AJMC Staff
New 340B Draft Guidance May Increase Bureaucracy
August 31, 2015 – Surabhi Dangi-Garimella, PhD
Synjardy Joins Ranks of Combo Therapies for Type 2 Diabetes
August 31, 2015 – Mary K. Caffrey

Sanofi Reports LixiLan-L Topline Results; Says Combo Superior to Insulin Alone

Mary K. Caffrey
Regulatory filings with the FDA are expected before the end of the year.
A combination of insulin glargine and the lixisenatide, a GLP-1 receptor agonist, showed superior results in helping patients with type 2 diabetes (T2D) control glycated hemoglobin (A1C) in a phase 3 trial, Sanofi reported today.

Sanofi released topline results of LixiLan-L, saying that the second pivotal trial for the drug combination met its primary endpoint. The study examined the efficacy and safety of a fixed-ratio combination of insulin glargine (Lantus), 100 units/mL, and lixisenatide versus treatment with insulin glargine 100 units/mL over a 30-week period. The study involved 736 patients with T2D whose A1C was not adequately controlled with basal insulin, either alone or in combination with 1 or 2 oral anti-diabetic agents. If patients were already taking metformin, that therapy was continued.

In July, Sanofi announced that the primary endpoint had been achieved in its first pivotal trial, LixiLan-O, which involved 1170 patients over a 30-week period. That trial involved patients whose T2D was not adequately controlled on metformin or metformin and another oral antidiabetic agent. In June, long-term cardiovascular (CV) results for lixisenatide were presented at the 75th Scientific Sessions of the American Diabetes Association, showing no CV risk or benefit.

In a statement, Sanofi said it expects to make regulatory submissions in the fourth quarter of 2015 with the FDA and in the first quarter of 2016 in Europe.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up